Personalized Cancer Vaccine Shows Early Promise Across Tumor Types Personalized Cancer Vaccine Shows Early Promise Across Tumor Types
In a phase 1 trial, the vaccine, called PGV-001, was well tolerated. It was given to 13 patients with multiple myeloma who had a high risk of recurrence after surgery or autologous stem cell transplant.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Health | Hematology | Myeloma | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants | Vaccines